Introduction
============

Lung cancer is the leading cause of cancer death accounting for 22.6%, and the incidence is the 4th in cancer statistics in Korea \[[@b1-roj-2016-01928]\]. The age-standardized incidence rate of lung cancer in men has decreased, while that in women has increased from 1999 to 2013. Although surgical resection is the treatment of choice for early stage non-small-cell lung cancer (NSCLC) patients, recurrence rates after surgery have been reported to be from 28% to 60%, and postrecurrence survival was poor \[[@b2-roj-2016-01928]-[@b4-roj-2016-01928]\]. The standard treatment for locoregionally recurrent NSCLC is still controversial. Repeated operation, radiation therapy, and concurrent chemoradiotherapy (CCRT) are considered for salvage local therapy. Even with the favorable survival outcomes, salvage reoperation is limited in selected patients \[[@b5-roj-2016-01928]\]. Alternatively, patients could be treated with salvage radiotherapy with or without chemotherapy. The recent National Comprehensive Cancer Network guideline recommends CCRT in case of mediastinal lymph node recurrence and superior vena cava obstruction \[[@b6-roj-2016-01928]\].

Several researchers have already evaluated treatment outcomes of recurrent NSCLC treated with salvage radiotherapy \[[@b7-roj-2016-01928]-[@b13-roj-2016-01928]\]. They reported the median survival ranging from 14 to 31 months. The survival of patients treated with salvage radiotherapy after recurrence was comparable to that of patients initially treated with radical radiotherapy \[[@b9-roj-2016-01928]\]. Furthermore, investigators demonstrated that CCRT could be a promising treatment modality for recurrent NSCLC \[[@b11-roj-2016-01928],[@b12-roj-2016-01928]\]. However, these studies were performed with relatively short follow-up period. Thus, these results might be exaggerated.

On the other hand, radiotherapy to the thorax can cause side effects. Some patients can experience a significant decrease in pulmonary function after curative radiotherapy, and cannot recover in long-term follow-up \[[@b14-roj-2016-01928]\]. In case of postoperative setting, these complications might be worse. According to a trial evaluating postoperative radiotherapy, high incidence of death, cardiac and respiratory complications were observed \[[@b15-roj-2016-01928]\]. Because previous studies have focused only on the treatment outcome of salvage radiotherapy, little information is available regarding toxicities of these patients.

This study retrospectively analyzed the survival outcomes and complications of patients with locoregionally recurrent NSCLC who were treated with salvage radiotherapy for a long-term follow-up period. We observed the changes of values of pulmonary functions tests after radiotherapy quantitatively.

Materials and Methods
=====================

1. Patients
-----------

This study was performed after the approval of the Institutional Ethical Review Board. We retrospectively reviewed the medical records of patients with recurrent NSCLC treated with salvage radiotherapy between 2004 and 2014. The inclusion criteria were as follows: (1) initially resected NSCLC under curative intention without adjuvant radiotherapy; (2) clinically or pathologically confirmed locoregional recurrence; (3) no evidence of distant metastasis; and (4) definitive aim radiotherapy for recurrent NSCLC. Locoregional recurrence was defined as a recurrence in contiguous sites to primary tumor or regional lymph nodal area. We identified 57 patients who fulfilled the inclusion criteria. When the recurrence was suspected, all patients underwent chest computed tomography (CT), 18-fluoro-deoxyglucose positron emission tomography-CT (PET-CT) and chest X-ray. Pathologic confirmation of the recurrence was done in 28 patients (49.1%). All patients were re-staged as if the patients had been newly diagnosed according to the 7th edition of the American Joint Committee on Cancer Staging.

2. Treatment
------------

Planning CT was obtained in a supine position with 3- or 4-mm slice thickness. Gross tumor volume (GTV) included recurrent tumor sites only regardless of primary location. Bronchial stump or ipsilateral hilar lymph nodes were not routinely included in the delineation of the clinical target volume (CTV). Lung parenchymal lesion was delineated in a pulmonary window, and mediastinal or hilar/interlobar lymph nodes were delineated in a mediastinal setting. CTV was defined by a 5- to 8-mm expansion from the GTV, and planning target volume was created by 10 mm margin from CTV. Radiotherapy was administered with 6--15 MV photons from linear accelerator with 3-dimensional conformal technique in all patients. The total dose was 45 to 70 Gy, delivered in daily fractions of 1.8 to 3.0 Gy. Thirty-one patients (54.4%) received 66 Gy in 33 fractions. Two patients received 2.5 Gy per fraction (65 Gy in 1 patient and 60 Gy in 1); 5 patients received 3 Gy per fraction (60 Gy in 2 patients, 54 Gy in 1, 51 Gy in 1, and 45 Gy in 1). Median biologically equivalent dose (BED, assuming α/β = 10) was 79.2 Gy (range, 58.5 to 84 Gy). Forty-two patients (73.7%) received concurrent chemotherapy in addition to radiotherapy. Chemotherapy regimen used in the treatment was weekly paclitaxel 50 mg/m^2^ combined with cisplatin 25 mg/m^2^ (n = 40) or triweekly etoposide 100 mg/m^2^ combined with cisplatin 70 mg/m^2^ (n = 2).

3. Follow-up
------------

Patients were regularly followed up with physical examination, blood tests, pulmonary function tests (PFTs) and chest CT. Radiologic tumor response to radiotherapy was evaluated using response evaluation criteria in solid tumors (RECIST) criteria by chest CT taken 1 month after radiotherapy. Locoregional recurrence was defined as recurrence in the primary tumor and a regional lymph nodal area. We also checked whether radiation in-field recurrence occurred or not. Distant metastasis was defined as recurrence in the ipsilateral different lobe, the contralateral lung, pleural nodules, malignant effusion, or extra-thoracic organs. Acute and late treatment related toxicities were evaluated by the physician according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.03. Complication occurred within 3 months from the start of radiotherapy was defined as acute complication, and after 3 months was as chronic complication. Patients performed PFTs including forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) at baseline and at 1, 6, and 12 months after radiotherapy. The results were also evaluated on the basis of each study's percentage of predicted of normal values adjusted for age, gender, and height.

4. Statistical analysis
-----------------------

Initial disease-free interval was calculated from the date of operation to the diagnosis of recurrence. Locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were calculated from the end day of radiotherapy to the event. Survival was estimated with the Kaplan-Meier method. The log-rank test and the Cox proportional hazard model were used for univariate and multivariate analyses, respectively. Multivariate analysis was performed on variables with a p-value \<0.1 in univariate analysis. Baseline and postradiotherapy PFT values were presented as mean ± standard deviation (SD) and analyzed using paired t-test. Factors with a p-value of less than 0.05 were regarded as statistically significant. All analyses were performed with PASW ver. 23.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

1. Patients and tumor characteristics
-------------------------------------

Patient characteristics are shown in [Table 1](#t1-roj-2016-01928){ref-type="table"}. The median age at the recurrence was 67 years (range, 34 to 81 years). There were 44 men and 13 women. Forty-eight patients (84.2%) showed an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 at the diagnosis of recurrence. Initial pathologic stage according to the TNM 7th edition was stage I in 25 patients (43.9%), stage II in 17 patients (29.8%), and stage III in 15 patients (26.3%). Initially, 47 patients (82.5%) received lobectomy. Adenocarcinoma and squamous cell carcinoma accounted for 40.4% each. Adjuvant chemotherapy was administered to 40 patients (70.2%). Median disease-free interval was 13.6 months (range, 1.4 to 57.4 months). In our cohort, the most commonly recurred site after surgery was superior mediastinal lymph nodal area (n = 25, 43.9%). As regard to the number of locoregional recurrent foci, single locoregional focus was in 37 patients (64.9%). The median volume of GTV was 39.9 cm^3^ (range, 1.0 to 283.4 cm^3^). There was significant difference in patients' age, PS, and rate of lung parenchymal recurrence between CCRT group and radiotherapy alone group (p \< 0.001, p = 0.034, and p = 0.001, respectively).

2. Treatment outcomes and failure patterns
------------------------------------------

The radiologic tumor response after radiotherapy was as follows: 6 patients (10.5%) achieved a complete regression, 39 patients (68.4%) achieved a partial regression, 10 patients (17.5%) had a stable disease, and 2 patients (3.5%) had progressive disease. The median follow-up time was 24 months (range, 3.0 to 119.8 months) for all patients, and 53.6 months (range, 12.0 to 107.5 months) for surviving patients. Treatment failure occurred in 39 patients (68.4%). Detailed patterns of failure are shown in [Table 2](#t2-roj-2016-01928){ref-type="table"}. Seventeen patients (29.8%) failed locoregionally, and 5 of them showed an isolated in-field recurrence. Thirty-one patients (54.4%) failed systemically. The most common site of distant metastasis was a contralateral lung, followed by pleura, brain, bone, and liver.

3. Survival and prognostic factors
----------------------------------

The median OS and PFS times were 54.8 months (range, 3.0 to 116.9 months) and 12.2 months (range, 0.8 to 100.2 months), respectively. The 2-year OS, PFS, LRFS, and DMFS rates were 62.4%, 33.6%, 70.9%, and 47.4%, respectively. The 5-year OS, PFS, LRFS, and DMFS rates were 48.5%, 20.5%, 63.8%, and 33.5%, respectively ([Fig. 1](#f1-roj-2016-01928){ref-type="fig"}).

[Table 3](#t3-roj-2016-01928){ref-type="table"} provides the results from univariate and multivariate analyses for OS. On univariate analysis, age, and concurrent chemotherapy were significant prognostic factors for OS. Multivariate analysis of revealed that multiple locoregional recurrent foci (p = 0.048) and radiotherapy alone (p = 0.001) were adverse prognostic factors for OS. [Fig. 2](#f2-roj-2016-01928){ref-type="fig"} illustrates the Kaplan-Meier curves according to the use of concurrent chemotherapy and the number of recurrence foci. Median OS were 86 months in patients receiving CCRT and 20 months in those receiving radiotherapy alone (p = 0.001) ([Fig. 2A](#f2-roj-2016-01928){ref-type="fig"}). In addition, median OS were 86 months in patients with a single recurrent focus and 21 months in those with multiple recurrent foci (p = 0.085) ([Fig. 2B](#f2-roj-2016-01928){ref-type="fig"}).

As regard to PFS, univariate analysis determined that age and the number of recurrent foci were significant prognostic factors ([Table 4](#t4-roj-2016-01928){ref-type="table"}). On multivariate analysis, single locoregional recurrent focus (p = 0.002) and the use of concurrent chemotherapy (p = 0.026) were independently associated with improved PFS. Seven patients (12.3%) were still alive without disease progression over 5 years after salvage treatment. All patients had a single locoregional recurrent focus, and 5 of 7 patients received CCRT.

4. Toxicity
-----------

The most common side effects were radiation pneumonitis and esophagitis. Acute radiation pneumonitis occurred in 19 patients (33.3%), with grade 1 in 5 (8.8%), grade 2 in 11 (19.3%), and grade 3 in 3 (5.3%). Esophagitis occurred in 27 patients (47.4%), with grade 1 in 9 (15.8%), grade 2 in 16 (28.1%), and grade 3 in 2 (3.5%). All acute toxicities were resolved and did not lead to chronic complications. Grade 4--5 toxicities were not observed in all patients.

PFT results at baseline and after radiotherapy were shown in [Fig. 3](#f3-roj-2016-01928){ref-type="fig"}. PFT at 1, 6, and 12 months were performed in 100%, 66.7%, and 56.1% of patients, respectively. Before radiotherapy, mean FEV1 ± SD was 2.03 ± 0.59 L (81.19% ± 19.07% predicted). Mean FEV1 ± SD at 1, 6, and 12 months after irradiation were 2.01 ± 0.55 L (81.57 ± 18.47% predicted), 1.95 ± 0.6 L (77.7% ± 19.53% predicted), and 2.0 ± 0.54 L (81.86% ± 18.69% predicted), respectively. Although there was no significant change in FEV1 at 1 month after radiotherapy, it declined at 6 months (p = 0.02). However, the change of FEV1 (% predicted) was not statistically significant. As regard to DLCO, mean DLCO ± SD was 15.57 ± 3.85 mL/min/mmHg (86.92% ± 15.85% predicted) before radiotherapy. Mean DLCO ± SD at 1, 6, and 12 months after radiotherapy were 13.71 ± 3.45 mL/min/mmHg (75.32% ± 16.46% predicted), 14.86 ± 3.86 mL/min/mmHg (83.22% ± 17.11% predicted), and 15.17 ± 3.95 mL/min/mmHg (84.84% ± 20.36% predicted), respectively. Although DLCO values significantly declined at 1 month after radiotherapy (p \< 0.001), it improved to the baseline level at 12 months.

Discussion and Conclusion
=========================

This is a retrospective study reporting clinical outcomes of salvage radiotherapy with or without chemotherapy in locoregionally recurrent NSCLC patients after radical surgery. In our study, salvage radiotherapy showed promising survival outcomes. Median OS and PFS were 54.8 months and 12.2 months, respectively, and these were significantly associated with concurrent chemotherapy and single recurrence focus. Although we observed a significant decrease in DLCO 1 month after radiotherapy, we did not observe the decrease in FEV1 and any chronic pulmonary complications.

Until now, there is no standard treatment for locoregional recurrent NSCLC after curative surgery. Several retrospective studies evaluated survival of patients with postoperative recurrent NSCLC in modern era ([Table 5](#t5-roj-2016-01928){ref-type="table"}). They reported that 2-year and median OS have ranged from 30% to 60% and 14 months to 31 months, respectively \[[@b7-roj-2016-01928]-[@b13-roj-2016-01928]\]. Our survival outcome is better than previous studies. This good clinical outcome in the present study could have resulted from the accurate re-staging with PET-CT, favorable patients with initially early-stage disease, good PS, and limited recurrent focus, the use of concurrent chemotherapy, and the adequate radiation dose in modern era.

The role of concurrent chemotherapy in post-resection recurrent NSCLC has not been well studied. For non-metastatic inoperable NSCLC patients, the European Organisation for Research and Treatment of Cancer (EORTC) performed a phase III randomized trial comparing cisplatin-based CCRT with radiotherapy \[[@b16-roj-2016-01928]\]. The study demonstrated that survival was significantly improved with CCRT. However, this clinical benefit came at the price of substantial side effects such as nausea, vomiting, and severe esophagitis. A systematic review evaluating radical CCRT also reported that CCRT significantly improved OS and PFS with the increased acute toxicity \[[@b17-roj-2016-01928]\]. In the salvage setting, Bar et al. \[[@b11-roj-2016-01928]\] reported clinical outcomes of 30 locoregional recurrent patients treated with CCRT. They used chemotherapy regimen as follows: platinum/vinorelbine (47%), carboplatin/paclitaxel (23%), cisplatin/etoposide (13%), and other platinum agents (17%). The median survival after recurrence was 26.9 months. Grade 4 toxicity occurred in 7 patients; 1 radiation pneumonitis, 1 pulmonary emboli, 5 febrile neutropenia. There was no severe radiation esophagitis. Takenaka et al. \[[@b12-roj-2016-01928]\] also analyzed the effect of CCRT for recurrent NSCLC. The median PFS and OS were 13 months (range, 4 to 127 months) and 31 months (range, 5 to 127 months), respectively. Chemotherapy included a platinum agent in all cases: cisplatin-based CCRT in 23, carboplatin-based CCRT in 12. Grade 3 esophagitis occurred in 3 patients (9%), and grade 4 hematologic toxicity occurred in 7 patients (20%). In our study, 42 patients were concurrently treated with weekly paclitaxel/cisplatin (n = 40) or triweekly etoposide/cisplatin (n = 2). Five patients experienced acute grade 3 toxicities, and chronic complications did not occur in our cohort. These results suggest that side effects of CCRT are tolerable in postoperative recurrent NSCLC patients.

Bae et al. \[[@b10-roj-2016-01928]\] reported the survival outcomes of high dose salvage radiotherapy for NSCLC patients with locoregional recurrence after resection. The median total BED~10~ was 70.2 Gy~10~ (range, 51.5 to 85.8 Gy~10~). There was a significant difference in the 2-year survival rates between BED ≤70.2 Gy~10~ and \>70.2 Gy~10~ groups (37.3% vs. 59.2%, p = 0.025). In the current study, the median BED was 79.2 Gy~10~ (range, 58.5 to 84 Gy~10~), and most patients except in two received radiotherapy higher than BED 70 Gy~10~. From our data, we could not find survival difference between BED \<79.2 Gy~10~ and ≥79.2 Gy~10~ groups. It suggests that increasing radiation dose does not improve survival when the radiation dose is adequate with a conformal technique.

In our investigation, all patients were evaluated with PET-CT before radiotherapy. It is valuable for accurate re-staging of the mediastinal lymph nodes. Although PET has a tendency to overestimate the disease extent, it could contribute to improve clinical outcomes and help to select appropriate patients for local therapy \[[@b18-roj-2016-01928]\]. We delineated the target volume based on PET images, and elective nodal irradiation was omitted. In this study, 39 patients (68.4%) showed treatment failure during follow-up period. Isolated in-field recurrence was reported in 5 patients (8.8%). Kelsey et al. \[[@b7-roj-2016-01928]\] used elective nodal irradiation in 27 of 29 NSCLC patients in salvage radiotherapy. They reported that 34.4% of patients showed failure within the radiation field despite elective nodal irradiation. Our locoregional recurrence rate (n = 17, 29.8%) is not different from elective nodal irradiated cases. In addition, distant metastasis (n = 31, 54.4%) was more dominant than locoregional recurrence in our study. Therefore, we suggest that omitting elective nodal irradiation does not result in poor clinical outcomes as salvage radiotherapy.

The prognostic factors for survival of recurrent NSCLC patients treated with salvage radiotherapy have been proposed by other investigators. PS, resection type, disease-free interval, CCRT, concurrent chemotherapy regimen, recurrence pattern, and GTV have been reported as prognostic factors for OS \[[@b9-roj-2016-01928],[@b10-roj-2016-01928],[@b12-roj-2016-01928],[@b13-roj-2016-01928]\]. In the present study, disease-free interval, PS, type of operation, and GTV volume did not show significant association with survival. We found that a single recurrent focus and CCRT significantly improved OS and PFS.

Postoperative radiotherapy could give an additional harm to patients who had already compromised lung function after surgery. In this study, we attempted to analyze the changes in PFTs in locoregional recurrent NSCLC patients treated with salvage radiotherapy. Our study revealed that patients receiving radiotherapy experienced a significant decrease in DLCO. Although DLCO declined significantly, grade 3 acute pneumonitis occurred in 3 patients (5.3%). In addition, previous studies did not report any severe complications. Based on these findings, it is thought that salvage radiotherapy with conformal technique is a safe treatment modality for recurrent NSCLC after radical resection.

This study had several limitations. First, this is a single institutional retrospective study. Intrinsic bias may have not been removed due to this nature. Second, included patient number was small and may restrict statistical power. Prospective studies with a large sample size are needed.

In summary, the present study indicated that salvage radiotherapy produced good survival outcomes in patients with recurrent NSCLC after surgery in the modern era. Although patients experienced a significant decline in DLCO immediately after radiotherapy, it recovered to pretreatment level within 12 months, and no one experienced significant chronic complications. In addition, a single recurrent focus and the use of concurrent chemotherapy were independent favorable prognostic factors for OS and PFS. These findings suggested that salvage radiotherapy combined with chemotherapy could be a promising therapy for selected patients with locoregional recurrence of NSCLC.
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###### 

Patients' characteristics

  Variable                             No. of patients (%)
  ------------------------------------ ---------------------
  Age (yr)                             67 (34-81)
  Gender                               
   Man                                 44 (77.2)
   Woman                               13 (22.8)
  ECOG performance status              
   0-1                                 48 (84.2)
   2                                   9 (15.8)
  Initial pathologic stage             
   I                                   25 (43.9)
   II                                  17 (29.8)
   III                                 15 (26.3)
  Initial operation                    
   Pneumonectomy                       5 (8.8)
   Bilobectomy                         2 (3.5)
   Lobectomy                           47 (82.5)
   Wedge resection                     3 (5.3)
  Histology                            
   Adenocarcinoma                      23 (40.4)
   Squamous cell carcinoma             23 (40.4)
   Others                              11 (19.3)
   Disease-free interval (mo)          13.6 (1.4-57.4)
  Recurrence stage                     
   I, II                               18 (31.6)
   III                                 39 (68.4)
  Recurrence site                      
   Superior mediastinal LN             25 (43.9)
   Hilar/interlobar LN                 15 (26.3)
   Lung parenchyma                     15 (26.3)
   Supraclavicular LN                  9 (15.8)
   Inferior mediastinal LN             9 (15.8)
   Bronchial stump                     6 (10.5)
   Aortic LN                           5 (8.8)
  No. of locoregional recurrent foci   
   1                                   37 (64.9)
   2                                   13 (22.8)
   3                                   7 (12.3)
  Salvage treatment                    
   CCRT                                42 (73.7)
   RT alone                            15 (26.3)
  GTV (cm^3^)                          39.9 (1.0-283.4)
  BED (Gy~10~)                         79.2 (58.5-84)
  Fractional dose (cGy)                
   180, 200                            50 (87.7)
   250, 300                            7 (12.3)

Values are presented as median (range) or number (%).

ECOG, Eastern Cooperative Oncology Group; LN, lymph node; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; GTV, gross tumor volume; BED, biologically equivalent dose.

###### 

Patterns of failure

  Variable                             No. of patients (%)
  ------------------------------------ ---------------------
  Recurrence                           
   Yes                                 39 (68.4)
   No                                  18 (31.6)
  Locoregional recurrence              17 (29.8)
   Isolated in-field recurrence        5 (8.8)
   Isolated out-field recurrence       3 (5.3)
   Locoregional + distant recurrence   9 (15.8)
  Distant recurrence                   31 (54.4)
   Isolated distant recurrence         22 (38.6)
   Locoregional + distant recurrence   9 (15.8)

###### 

Univariate and multivariate analyses for OS

  Variable                     No.   Univariate   Multivariate                         
  ---------------------------- ----- ------------ -------------- ------- ------------- -------
  Age (yr)                                        0.005                                0.423
   \<70                        37    63.9                        \-      \-            
   ≥70                         20    40.0                        \-      \-            
  Disease-free interval (mo)                      0.257                                \-
   ≥15                         27    61.0                        \-      \-            
   \<15                        30    63.3                        \-      \-            
  No. of recurrent foci                           0.085                                0.048
   1                           37    70.3                        1.000   \-            
   2, 3                        20    46.7                        2.132   1.006-4.519   
  Concurrent chemotherapy                         0.001                                0.001
   No                          15    33.3                        1.000   \-            
   Yes                         42    73.1                        0.303   0.147-0.624   
  BED (Gy~10~)                                    0.704                                \-
   \<79.2                      19    63.2                        \-      \-            
   ≥79.2                       38    62.0                        \-      \-            
  GTV (cm^3^)                                     0.989                                \-
   \<40                        30    60.0                        \-      \-            
   ≥40                         27    65.4                        \-      \-            
  Initial tumor response                          0.129                                0.108
   CR                          6     83.3                        \-      \-            
   PR, SD, PD                  51    59.8                        \-      \-            

OS, overall survival; HR, hazard ratio; CI, confidence interval; BED, biologically equivalent dose; GTV, gross tumor volume; CR, complete regression; PR, partial regression; SD, stable disease; PD, progressed disease.

###### 

Univariate and multivariate analyses for PFS

  Variable                     No.   Univariate   Multivariate                          
  ---------------------------- ----- ------------ -------------- ------- -------------- -------
  Age (yr)                                        0.019                                 0.283
   \<70                        37    41.1                        \-      \-             
   ≥70                         20    20.0                        \-      \-             
  Disease-free interval (mo)                      0.604                                 \-
   ≥15                         27    39.1                        \-      \-             
   \<15                        30    28.5                        \-      \-             
  No. of recurrent foci                           0.010                                 0.002
   1                           37    45.2                        1.0     \-             
   2, 3                        20    9.0                         2.935   1.508--5.714   
  Concurrent chemotherapy                         0.065                                 0.026
   No                          15    20.0                        1.0     \-             
   Yes                         42    38.2                        0.467   0.239--0.913   
  BED (Gy~10~)                                    0.928                                 \-
   \<79.2                      19    36.8                        \-      \-             
   ≥79.2                       38    31.8                        \-      \-             
  GTV (cm^3^)                                     0.623                                 \-
   \<40                        30    36.7                        \-      \-             
   ≥40                         27    29.4                        \-      \-             
  Initial tumor response                          0.274                                 \-
   CR                          6     66.7                        \-      \-             
   PR, SD, PD                  51    29.9                        \-      \-             

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; BED, biologically equivalent dose; GTV, gross tumor volume; CR, complete regression; PR, partial regression; SD, stable disease; PD, progressed disease.

###### 

Results of radiotherapy for locoregionally recurrent non-small-cell lung cancer

  Author                                      Period       No. of patients   Initial stage I-II   CCRT        Median RT dose (Gy)   2-yr OS (%)   Median OS (mo)   Median PFS (mo)   Prognostic factors in OS
  ------------------------------------------- ------------ ----------------- -------------------- ----------- --------------------- ------------- ---------------- ----------------- ------------------------------------------------
  Kelsey et al. \[[@b7-roj-2016-01928]\]      1991--2003   29                28 (96.6)            15 (51.7)   66 (46--74)           38            17               \-                None
  Tada et al. \[[@b8-roj-2016-01928]\]        1992--2002   31                \-                   5 (16.1)    60                    30.0          14               \-                \-
  Cai et al. \[[@b9-roj-2016-01928]\]         1992--2004   54                8 (14.8)             22 (40.7)   \>59.4                5-yr: 14.8    19.8             \-                None
  Bae et al. \[[@b10-roj-2016-01928]\]        1994--2007   64                54 (84.4)            14 (21.9)   54 (44--66)           47.9          18.5             \-                Disease-free interval, concurrent chemotherapy
  Bar et al. \[[@b11-roj-2016-01928]\]        1999--2009   30                26 (86.7)            30 (100)    63.5 (26--66)         50.8          26.9             \-                None
  Takenaka et al. \[[@b12-roj-2016-01928]\]   2000--2011   35                20 (57.1)            35 (100)    60 (30--60)           60.0          31               13                ECOG PS, resection type, chemotherapy regimen
  Lee et al. \[[@b13-roj-2016-01928]\]        2001--2009   38                23 (60.5)            12 (31.6)   60 (45--75)           56.0          27.9             22                GTV, recurrence pattern
  Current study                               2004--2014   57                42 (73.7)            42 (73.7)   66 (45--70)           62.4          54.8             12.2              No. of recurrent foci, concurrent chemotherapy

Values are presented as number (%) or median (range).

CCRT, concurrent chemoradiotherapy; RT, radiotherapy; OS, overall survival; PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; GTV, gross tumor volume.
